A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

3期 进行中（已停止招募） NCT04175600

摘要

The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.

Double-blind Period: Time to Disease Progression

Placebo arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 199 weeks); Selexipag arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 213 weeks) · Months

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
• Improving Hypertension Medication Adherence for Older Adults — University of Arizona
• LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
• SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca
• Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test — Stanford University

全部试验